Akums gets ₹133.75 cr tax notice, says it will appeal
IT assessment demands 52% of FY26 profit, but management calls it unsustainable and plans to challenge.
— 1 earlier story on Akums Drugs & Pharmaceuticals Ltd. →What's new
- Received IT assessment order under Section 158BC with ₹133.75 cr demand.
- Management considers demand unsustainable, plans to appeal.
- Matter was already flagged in auditor's emphasis in recent results.
Why it matters
A ₹133.75 crore tax demand is material — 52% of FY26 net profit. But contest risk is high; management intends to appeal. Until resolved, it's an overhang, not a charge.
What we're watching
- Outcome of appeal and any tax provision in future quarters.
- Whether the demand escalates or gets reduced on adjudication.
- Impact on cash flows if a partial payment is required.
The full read
Akums Drugs & Pharmaceuticals has received an income tax assessment order under Section 158BC for a block period spanning 2018 to 2025, with total demands aggregating to approximately ₹133.75 crore — about 52% of the company's FY26 consolidated net profit of ₹255.19 crore. Management has stated that it considers the demands legally unsustainable and intends to appeal the order. The tax search and potential liabilities were already highlighted as an emphasis of matter by the auditor in recent annual results, so the development was not entirely unforeseen. Given the company's defensive stance and the uncertainty around eventual payment, the immediate financial impact remains unclear. The event is notable but not a definitive earnings shock, limiting its market-moving potential for now.